Memphasys (ASX:MEM) said the publication of a study in the "Antioxidants" journal reinforces the commercial potential as well as the scientific credibility of its RoXsta platform to identify oxidative stress in human and animal samples, according to a Thursday Australian bourse filing.
RoXsta is a proprietary antioxidant diagnostic platform for identifying oxidative stress-related deficiencies, and the study supports its ability to diagnose oxidative stress through analysis of biological fluids, the filing added.
The RoXsta system has potential for male infertility treatments as well as disease management in conditions such as neurodegenerative diseases, cardiovascular disorders, and cancer, the filing said.
It is also exploring its potential for the optimization of livestock productivity by mitigating oxidative stress.
Oxidative stress is linked to infertility, cardiovascular disease, neurodegenerative disorders, cancer, and other conditions, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。